Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Motor function optimization with galantamine in advanced Parkinson's disease patients with visual hallucinations
2008-006278-13Phase 4Active
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2008
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of galantamine in Parkinson's disease (PD) and Visual hallucination (VH) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Change in severity of visual hallucinations. Started Oct 2008; status: active.
02
Drugs
galantamine
03
Conditions
Parkinson's disease (PD)Visual hallucination (VH)
Beyond the preview
Go deeper on 2008-006278-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006278-13.